CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) (USD $)	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011
Cash flows from operating activities:
Net loss	$ (6,057,092)	$ (7,616,791)
Adjustments to reconcile net loss to net cash flows from operating activities:
Depreciation	354,425	330,851
Amortization of intangible assets	1,117,646	1,001,931
Impairment of intangible assets	1,798,495	0
Amortization of debt discount and deferred financing costs	1,222,289	246,807
Employee share-based compensation expense	1,432,627	1,032,261
Other share-based compensation expense	323,042	285,154
Change in fair value adjustment of earn-out liability	1,320,000	0
Increase (decrease) in cash resulting from changes in (net of effects of acquisition):
Accounts receivable	(4,278,205)	(818,102)
Inventory	(1,089,733)	(150,479)
Prepaid expenses and other current assets	(382,051)	(161,010)
Other assets	19,213	(48,174)
Accounts payable and accrued expenses	1,446,864	833,013
Accrued interest	312,775	65,281
Other liabilities	(1,408)	(9,825)
Net cash flows from operating activities	(2,461,113)	(5,009,083)
Cash flows from investing activities:
Purchases of equipment	(401,864)	(417,900)
Cash paid for acquisition, net of cash acquired of $33,583	0	(466,417)
Net cash flows from investing activities	(401,864)	(884,317)
Cash flows from financing activities:
Proceeds from exercise of warrants	5,925,539	0
Proceeds from exercise of stock options	885,034	295,753
Repayment of convertible debt related to acquisition	(427,126)	0
Repayment of equipment lease	(11,002)	0
Repurchase of warrants	(568)	0
Proceeds from line of credit with related party	0	1,300,000
Repayment of line of credit	0	(99,000)
Repayment of notes payable	0	(50,671)
Proceeds from sale of common stock and warrants and common stock with registration rights, net	0	3,743,588
Net cash flows from financing activities	6,371,877	5,189,670
Net change in cash	3,508,900	(703,730)
Cash, beginning of period	4,112,326	1,340,922
Cash, end of period	7,621,226	637,192
Supplemental disclosure of cash flow information:
Cash paid for interest	8,738	4,842
Cash paid for income taxes	0	0
Supplemental disclosure of non-cash financing activity:
Common stock issued for accrued Director fees (in shares)	167,086
Common stock issued for accrued Director fees	184,653
Cashless exercise of warrants (in shares)	216,085
Deferred financing costs	9,537
Beneficial conversion feature recognized	514,456	80,000
Stock valued for payment of earn out liability related to acquisition of Surgical Biologics, LLC (in shares)	2,632,576
Stock valued for payment of earn out liability related to acquisition of Surgical Biologics, LLC	3,185,223
Equipment acquired under capital lease	83,016
Common stock issued for payment of the convertible secured promissory notes (in shares)	893,267
Common stock issued for payment of the convertible secured promissory notes	893,267
Shares issued for conversion of convertible debt and accrued interest to equity (in shares)		406,664
Shares issued in conjunction with the acquisition of Surgical Biologics, LLC (in shares)		5,250,000
Stock valued in conjunction with the acquisition of Surgical Biologics, LLC		7,087,500
Beneficial conversion feature value related to the convertible debt issued with regard to the acquisition of Surgical Biologics, LLC		437,500
Convertible debt issued with regard to acquisition of Surgical Biologics		$ 1,250,000